This week, Baxter International, Inc. announced it received clearance from the U.S. Food and Drug Administration (FDA) for its Novum IQ large volume infusion pump (LVP) with its Dose IQ Safety Software, powered by the IQ Enterprise connectivity suite. Together, these three components make for a powerful solution for clinicians to utilize a single, integrated system for a variety of treatments.

According to Heather Knight, vice president and group president of Medical Products and Therapies at Baxter said, “Our goal, always, is to bring increased efficiency, safety and opportunity for informed decision-making to our customers, clinicians and patients they serve.”

Through the Novum IQ, intelligent infusion therapy can make a huge difference in the patient—and clinician, experience.

In the wake of hospital turnover, burnout, and staffing shortages, along with an increased focus on cost reductions while improving patient outcomes, the Novum IQ platform can help reduce non-critical tasks from nurses’ plates, allowing them and other clinicians to focus more on patient care.

Not only does the Novum IQ LVP and the Novum IQ syringe infusion pump (SYR)streamlines clinician training and reduces cognitive burdens of operating multiple pump platforms, but coupled with the Dose IQ Safety Software, hospitals are up to date with the latest facility-specific drug and dosage parameters and information. This runs on top of the IQ Enterprise connectivity suite, which means that hospitals have access to a bi-directional electronic medical record (EMR), enhanced continuous quality improvement (CQI) reports, and seamless software updates. 

Healthcare of the future is personalized, frictionless, and intelligent.